Last year, more than $7.5 billion globally went to companies applying advances in artificial intelligence to health-related areas such as medical services and pharmaceutical development, per ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Based in part on these favorable pre-clinical results, a clinical trial using VAS-101 in individuals with sickle cell disease will soon be initiated ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its ...